
Günter Breithardt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1232779/publications.pdf Version: 2024-02-01



2.2

69

#	Article	IF	CITATIONS
1	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. European Heart Journal, 2022, 43, 1219-1230.	2.2	84
2	Thyroid Dysfunction under Amiodarone in Patients with and without Congenital Heart Disease: Results of a Nationwide Analysis. Journal of Clinical Medicine, 2022, 11, 2027.	2.4	3
3	Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm ControlÂTherapy. Journal of the American College of Cardiology, 2022, 80, 283-295.	2.8	34
4	The dawn of radiofrequency catheter ablation for cardiac arrhythmias. Heart Rhythm, 2021, 18, 485-486.	0.7	4
5	Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET). Europace, 2021, 23, 1903-1912.	1.7	15
6	Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation, 2021, 144, 845-858.	1.6	111
7	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. Journal of the American Heart Association, 2021, 10, e022485.	3.7	0
8	Ludger Seipel: an early comer in clinical electrophysiology at 80 years. Clinical Research in Cardiology, 2020, 109, 527-528.	3.3	0
9	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine, 2020, 383, 1305-1316.	27.0	1,071
10	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 145-152.	4.0	75
11	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. International Journal of Cardiology, 2018, 257, 78-83.	1.7	10
12	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. American Heart Journal, 2018, 200, 102-109.	2.7	6
13	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. Clinical Cardiology, 2018, 41, 39-45.	1.8	11
14	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. Circulation, 2017, 135, 1001-1003.	1.6	30
15	NOACs for Stroke Prevention in AtrialÂFibrillation With Valve Disease. Journal of the American College of Cardiology, 2017, 69, 1383-1385.	2.8	2
16	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) Tj ETQqO 0 C) rgBT /Ove	erlock 10 Tf
17	Cardiology, 2017, 120, 1837-1840. Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003337.	4.8	213

18 Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. European Heart Journal, 2016, 38, ehv643.

Günter Breithardt

#	Article	IF	CITATIONS
19	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart, 2016, 102, 1036-1043.	2.9	36
20	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European Heart Journal, 2015, 36, 288-296.	2.2	266
21	Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term. European Heart Journal, 2015, 36, 1794-1797.	2.2	14
22	Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry. BMC Neurology, 2015, 15, 129.	1.8	22
23	Dronedarone and digitalis: individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias. Europace, 2015, 17, 1300-1308.	1.7	19
24	Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives. Cardiovascular Diagnosis and Therapy, 2015, 5, 364-73.	1.7	34
25	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European Heart Journal, 2014, 35, 3377-3385.	2.2	154
26	The quality of oral anticoagulation in general practice in patients with atrial fibrillation. European Journal of Internal Medicine, 2014, 25, 247-254.	2.2	30
27	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014. 130. 138-146.	1.6	345
28	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 651-658.	2.8	181
29	Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. American Heart Journal, 2013, 166, 442-448.	2.7	132
30	Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace, 2013, 15, 486-493.	1.7	308
31	Oral anticoagulation use by patients with atrial fibrillation in Germany. Thrombosis and Haemostasis, 2012, 107, 1053-1065.	3.4	122
32	Left Bundle Branch Block, an Old–New Entity. Journal of Cardiovascular Translational Research, 2012, 5, 107-116.	2.4	43
33	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 883-891.	27.0	8,006
34	Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. Thrombosis and Haemostasis, 2011, 105, 1010-1023.	3.4	69
35	MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization) Tj ETQq1 1 0.7843 Heart Journal, 2009, 30, 2551-2553.	14 rgBT /0 2.2	Overlock 10 15
36	The German Competence Network on Atrial Fibrillation (AFNET). Herz, 2008, 33, 548-555.	1.1	12

#	Article	IF	CITATIONS
37	The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace, 2008, 11, 423-434.	1.7	352
38	Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace, 2007, 9, 1006-1023.	1.7	254
39	Doppler echocardiography and Tissue Doppler Imaging in the healthy rabbit: Differences of cardiac function during awake and anaesthetised examination. International Journal of Cardiology, 2007, 115, 164-170.	1.7	48
40	Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial. Clinical Drug Investigation, 2007, 27, 697-705.	2.2	34
41	Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). European Heart Journal, 2007, 28, 2803-2817.	2.2	335
42	Quest for the Best Candidate. Circulation, 2006, 113, 926-928.	1.6	20
43	Atrial fibrillation management: a prospective survey in ESC Member Countries. European Heart Journal, 2005, 26, 2422-2434.	2.2	770
44	Targeted pharmacological reversal of electrical remodeling after cardioversion—Rationale and design of the Flecainide Short-Long (Flec-SL) trial. American Heart Journal, 2005, 150, 899.e1-899.e6.	2.7	31
45	Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal, 2004, 25, 1385-1394.	2.2	300
46	Prolonged Atrial Action Potential Durations and Polymorphic Atrial Tachyarrhythmias in Patients with Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 2003, 14, 1027-1033.	1.7	119
47	Directct Epicardial Mapping Can Differentiate Hibernating from Scarred Myocardium: A Validation Study with 18F-FDG-PET. Annals of Noninvasive Electrocardiology, 2002, 7, 349-356.	1.1	3
48	A novel long-QT 5 gene mutation in the C-terminus (V109I) is associated with a mild phenotype. Journal of Molecular Medicine, 2001, 79, 504-509.	3.9	29
49	Intracardiac Tuberculoma Causing "Idiopathic" Ventricular Tachycardia in a Patient Without Detectable Heart Disease. Journal of Cardiovascular Electrophysiology, 2001, 12, 118-118.	1.7	5
50	Clinical Value of Electrocardiographic Parameters in Genotyped Individuals with Familial Long QT Syndrome. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 406-415.	1.2	12
51	Prolonged QRS Duration Increases QT Dispersion But Does Not Relate to Arrhythmias in Survivors of Acute Myocardial Infarction. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 789-795.	1.2	12
52	Absence of circulating microemboli in patients with lone atrial fibrillation. Neurological Research, 1999, 21, 566-568.	1.3	11
53	KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nature Genetics, 1997, 17, 267-268.	21.4	441
54	The clinical impact of thallium-201 reinjection for the detection of myocardial hibernation. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 407-413.	2.1	14

#	Article	IF	CITATIONS
55	Internal Defibrillation with Smaller Capacitors: A Prospective Randomized Cross-Over Comparison of Defibrillation Efficacy Obtained with 90-?F and 125-?F Capacitors in Humans. Journal of Cardiovascular Electrophysiology, 1995, 6, 333-342.	1.7	16
56	Bipolar Transvenous Defibrillation: Efficacy of Two Different Positions of the Anode. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 1995-2000.	1.2	7
57	Are there gender differences in patients with coronary artery disease presenting with spontaneous sustained ventricular tachycardia and ventricular fibrillation?. Clinical Cardiology, 1995, 18, 161-166.	1.8	7
58	Trans venous-Subcutaneous Defibrillation Leads: Journal of Cardiovascular Electrophysiology, 1994, 5, 912-918.	1.7	12
59	Recurrence and Late Block of Accessory Pathway Conduction Following Radiofrequency Catheter Ablation. Journal of Cardiovascular Electrophysiology, 1994, 5, 650-658.	1.7	25
60	A Prospective Randomized Cross-Over Comparison of Mono- and Biphasic Defibrillation Using Nonthoracotomy Lead Configurations in Humans. Journal of Cardiovascular Electrophysiology, 1994, 5, 581-590.	1.7	66
61	Management of Patients with Ventricular Tachyarrhythmias: Does an Optimal Therapy Exist?. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 559-570.	1.2	7
62	Radiofrequency Catheter Ablation of Ventricular Tachycardia Following Implantation of an Automatic Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 1684-1692.	1.2	54
63	Signal Averaging in Patients withCoronary Artery Disease: Journal of Cardiovascular Electrophysiology, 1993, 4, 609-626.	1.7	7
64	Unexpected Emergence of Manifest Preexcitation Following Transcatheter Ablation of Concealed Accessory Pathways. Journal of Cardiovascular Electrophysiology, 1993, 4, 467-472.	1.7	8
65	Nd: YAG Laser-Photocoagulation: Acute Electrophysiological, Hemodynamic, and Morphological Effects in Large Irradiated Areas. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 52-59.	1.2	4
66	Radiofrequency Ablation of Accessory Pathways: Characteristics of Transiently and Permanently Effective Pulses. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 1122-1130.	1.2	16
67	Results and Realistic Expectations with Transvenous Lead Systems. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 665-670.	1.2	56
68	Implantation of a Cardioverter/Defibrillator in the Subpectoral Region Combined with a Nonthoracotomy Lead System. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 367-368.	1.2	27
69	Role of Ventricular Tachycardia Surgery and Catheter Ablation As Complements or Alternatives To the Implantable Cardioverter Defibrillator in the 1990s. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 681-689.	1.2	12
70	Coagulation of Ventricular Myocardium Using Radiofrequency Alternating Current: Bio-Physical Aspects and Experimental Findings. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 187-195.	1.2	87
71	High frequency alternating current ablation of an accessory pathway in humans. Journal of the American College of Cardiology, 1987, 10, 576-582.	2.8	257
72	Electrical and Anatomical Mapping of Different Pathologies: Ischemic, Dilated, and Hypertrophic		0

Cardiomyopathies. , 0, , 376-384.

#	Article	IF	CITATIONS
73	Principles of NavX Mapping. , 0, , 71-79.		0
74	Cardiac Anatomy for Interventional Electrophysiology and Mapping. , 0, , 27-36.		0
75	Legal Implications of Defibrillator Guidelines. , 0, , 60-62.		Ο
76	Construction and Interpretation of Endocardial Maps: From Basic Electrophysiology to 3D Mapping. , 0, , 11-26.		1
77	Molecular Cardiovascular Imaging with SPECT and PET. , 0, , 454-462.		Ο
78	Role of Body Surface Mapping. , 0, , 485-491.		0
79	Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET): Authors' reply.	1.7	0